PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
Abstract
Authors
L Cardozo A Thorpe M Grishchenko MK Sidhu